Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonists

Journal of Hypertension

Volumn 15, Issue 11, 1997, Pages 1197-1200

  Psaty, Bruce M ^a   Furberg, Curt D ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium antagonists; Coronary disease; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST;

ANGINA PECTORIS; CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE POLICY; HEALTH SERVICE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MANAGEMENT; MEDICAL INFORMATION; PATIENT; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 0030687610     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715110-00001     Document Type: Short Survey

References (22)

1. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Koepsell TD, Weiss NS, et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625.
2. Furberg CD, Psaty BM, Myers JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331 [correction in Circulation 1996, 93:1475-1476].
3. Pahor M, Guralnik JM, Cortic MC, Foley JD, Carbonin P, Havlik RJ: Long-term survival and use of antihypertensive medication in older persons. J Am Geriatr Soc 1995, 43:1191-1197.
4. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996, 347:1061-1065.
5. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al.: Calcium channel blockers and incidence of cancer in aged populations. Lancet 1996, 348:493-497.
6. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR: Calcium-channel blockers and risk of cancer. Lancet 1997, 349:525-528.
7. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension: Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997, 15:105-115.
8. Gheorghiade M, Weiner DA, Chakko S, Lessem JN, Klein MD: Monotherapy of stable angina with nicardipine hydrochloride: double-blind, placebo-controlled, randomized study. Eur Heart J 1989, 10:695-701.
9. Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D: Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial. Am J Cardiol 1986, 58:715-721.
10. Tadani U, Sellner SR, Glasser S, et al.; Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: a new second-generation calcium channel blocker in angina pectoris. Circulation 1991, 84:2398-2408.
11. Gong L, Zwang W, Zhu Y, et al.: Shanghai Trial of Nifedipine in the Elderly (STONE) study. J Hypertens 1996, 14:1237-1246.
12. Borhani NO, Mercuri M, Borhanti PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276:785-791.
13. Chobanian AV: Calcium channel blockers: lessons learned from MIDAS and other clinical trials [editorial]. JAMA 1996, 276:829-830.
14. Hennekens CH, Buring JE: Observational evidence. Ann NY Acad Sci 1993, 703:18-24.
15. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 232:1589-1593.
16. Psaty BM, Siscovick DS, Weiss NS, Koepsell TD, Rosendaal FR, Lin D, et al.: Hypertension and outcomes research: from clinical trials to clinical epidemiology. Am J Hypertens 1996, 9:178-183.
17. Stolley PD: A public health perspective from academia. In Pharmacoepidemiology. Second Edition. Edited by Strom BL. New York: John Wiley and Sons; 1994.
18. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE: Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996, 335:1660-1667.
19. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al.: ACC/AH guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute MI). J Am Coll Cardiol 1996, 28:1328-1428.
20. Psaty BM, Smith NS, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997, 277:739-745.
21. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. for the ALLHAT Research Group: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996, 9:342-360.
22. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993, 153:154-183.